These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36927434)

  • 1. Monoclonal CCR5 Antibody: A Promising Therapy for HIV.
    Zhao L; Lai Y
    Curr HIV Res; 2023; 21(2):91-98. PubMed ID: 36927434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of CCR5 antibodies against HIV: current and future aspects.
    Prathipati PK; Mandal S; Destache CJ
    Ther Deliv; 2019 Feb; 10(2):107-112. PubMed ID: 30729884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing HIV transmission through blockade of CCR5: rationale, progress and perspectives.
    Hartley O; Martins E; Scurci I
    Swiss Med Wkly; 2018; 148():w14580. PubMed ID: 29376550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.
    Mohamed H; Gurrola T; Berman R; Collins M; Sariyer IK; Nonnemacher MR; Wigdahl B
    Front Immunol; 2021; 12():816515. PubMed ID: 35126374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.
    Jekle A; Chhabra M; Lochner A; Meier S; Chow E; Brandt M; Sankuratri S; Cammack N; Heilek G
    Antimicrob Agents Chemother; 2010 Feb; 54(2):734-41. PubMed ID: 19995923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
    Latinovic O; Le N; Reitz M; Pal R; DeVico A; Foulke JS; Redfield RR; Heredia A
    AIDS; 2011 Jun; 25(9):1232-5. PubMed ID: 21505306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology of CCR5 and its role in HIV infection and treatment.
    Lederman MM; Penn-Nicholson A; Cho M; Mosier D
    JAMA; 2006 Aug; 296(7):815-26. PubMed ID: 16905787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances of CCR5 antagonists: From small molecules to macromolecules.
    Qi B; Fang Q; Liu S; Hou W; Li J; Huang Y; Shi J
    Eur J Med Chem; 2020 Dec; 208():112819. PubMed ID: 32947226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-based strategies in HIV therapy.
    Kufel WD
    Int J Antimicrob Agents; 2020 Dec; 56(6):106186. PubMed ID: 33045349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
    Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM
    J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
    Xu GG; Guo J; Wu Y
    Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.
    Anderson JS; Walker J; Nolta JA; Bauer G
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):152-61. PubMed ID: 19593160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research progress on chemokine receptor 5-targeted therapy for HIV-1].
    Wang YJ; Zhang JQ
    Bing Du Xue Bao; 2014 Jan; 30(1):79-83. PubMed ID: 24772903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
    Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
    Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
    J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
    Latinovic O; Reitz M; Le NM; Foulke JS; Fätkenheuer G; Lehmann C; Redfield RR; Heredia A
    Virology; 2011 Mar; 411(1):32-40. PubMed ID: 21232779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lupane-type triterpene 30-oxo-calenduladiol is a CCR5 antagonist with anti-HIV-1 and anti-chemotactic activities.
    Barroso-González J; El Jaber-Vazdekis N; García-Expósito L; Machado JD; Zárate R; Ravelo ÁG; Estévez-Braun A; Valenzuela-Fernández A
    J Biol Chem; 2009 Jun; 284(24):16609-16620. PubMed ID: 19386595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 monoclonal antibodies for HIV-1 therapy.
    Olson WC; Jacobson JM
    Curr Opin HIV AIDS; 2009 Mar; 4(2):104-11. PubMed ID: 19339948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.